Core Insights - InnovAge Holding Corp. will release its 2025 fiscal fourth quarter and full year financial results on September 9, 2025, after market close [1] - A conference call to review the results will be held at 5 p.m. E.T. on the same day [1] Company Overview - InnovAge is a leader in managing care for high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE) [3] - The company's mission is to enable older adults to age independently in their homes for as long as safely possible [3] - As of March 31, 2025, InnovAge served approximately 7,530 participants across 20 centers in six states [3]

Core Insights - International Money Express, Inc. (Intermex) has announced a strategic partnership with Zeepay to enhance money remittance services for African communities abroad, particularly targeting Africans in the United States [1][2] - The collaboration will utilize Intermex's Wire-as-a-Service platform combined with Zeepay's regional network to facilitate money transfers across Africa and expand services through Zeepay's retail stores in the U.S. and digital channels in Europe [2][3] Company Overview - Intermex, founded in 1994, specializes in enabling money transfers from various countries to over 60 destinations, utilizing a network of agent retailers, company-operated stores, mobile apps, and websites [5] - The company is headquartered in Miami, Florida, with international offices in Puebla, Guatemala City, London, and Madrid [5] - Zeepay is a Ghanaian fintech company focused on mobile financial services, regulated by the Bank of Ghana and the UK Financial Conduct Authority, with a strong emphasis on remittances and mobile money [4]

Core Insights - FLUENT Corp. reported its largest harvest in history from the Rosa cultivation facility, marking a significant operational milestone [1][3] - The company has initiated operations at the Buffalo cultivation facility through an exclusive partnership with Connected Cannabis, aiming to enhance product quality and meet growing demand [1][3] - A new Interim CEO has been appointed to lead the company's strategic and operational turnaround efforts [1][2] Financial Highlights - Q2 2025 revenue was $26.7 million, a slight decrease from $27.3 million in Q2 2024 [7] - Florida revenue specifically dropped to $19.3 million from $23.1 million year-over-year [7] - Gross profit before fair value adjustments was $10.4 million, representing 39% of revenue, down from $13.8 million or 50.5% of revenue in the previous year [7] - Adjusted EBITDA decreased to $3.9 million from $7.7 million, primarily due to lower revenue and increased production costs [7] - As of June 30, 2025, the company had approximately $22.9 million in cash and cash equivalents and $78.1 million in total debt, compared to $8.5 million and $67.5 million respectively a year earlier [7] Operational Highlights - FLUENT operates 42 retail locations and 8 production facilities across Florida, New York, Pennsylvania, and Texas [5] - The Rosa facility's inaugural harvest in August was the largest in the company's history, indicating a strong cultivation platform [3][8] - The Buffalo facility's partnership with Connected Cannabis is expected to enhance indoor cultivation capacity and product quality, with products anticipated to be available by late Q4 2025 [3][8] Strategic Initiatives - The company is focusing on operational excellence, customer-centered approaches, and disciplined cost management as part of its strategic turnaround [2] - A review of the Florida retail network is underway to drive profitable growth [8] - The growth of the ENTOURAGE wholesale division remains a priority to enhance wholesale revenue across the state [15]

Group 1 - Cogent Biosciences, Inc. announced participation in the Citi Biopharma Back to School Conference on September 3, 2025, at 9:00 a.m. ET [1] - A live webcast of the event will be available on Cogent's Investors & Media page, with a replay accessible for 30 days post-event [2] - The Compensation Committee approved inducement equity awards for two new employees, granting nonqualified options to purchase 54,500 shares of common stock, with a 10-year term and a four-year vesting schedule [3] Group 2 - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its leading clinical program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors [4] - The company is also conducting a Phase 1 study of a novel FGFR2/3 inhibitor and developing targeted therapies for mutations in ErbB2, PI3Kα, and KRAS [4] - Cogent is headquartered in Waltham, MA, and Boulder, CO, and provides updates on its website and social media platforms [4]

Core Viewpoint - Red Cat Holdings, Inc. has launched a new division, Blue Ops, Inc., to develop battle-tested uncrewed surface vessel (USV) weapons systems, aiming to meet the evolving demands of modern warfare [1][2][3] Company Overview - Red Cat is a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, expanding its capabilities into the maritime domain through Blue Ops [10] - The company operates through subsidiaries Teal Drones and FlightWave Aerospace, focusing on military, government, and public safety operations across air, land, and sea [10] New Division - Blue Ops - Blue Ops will design, build, and deploy modular USVs to support multi-domain military and security missions, complementing existing divisions [2][5] - Barry Hinckley, a veteran in the marine industry, has been appointed as President of Blue Ops, bringing extensive experience in maritime leadership [4][5] Strategic Importance - The establishment of Blue Ops aligns with the U.S. Navy's modernization efforts and the need for fleet readiness in potential conflicts, particularly in the South China Sea [3][6] - The division aims to integrate autonomous vehicles into naval operations, leveraging America's shipbuilding industry to provide scalable solutions [3][6] Technological Integration - Blue Ops plans to incorporate various sensors and capabilities into its USV systems, enhancing operational effectiveness across multiple domains [7] - The division will focus on creating smaller, smarter, uncrewed platforms that can operate in environments where traditional vessels may not be effective [5] Manufacturing and Production - Blue Ops is preparing to launch U.S.-based production of its USV systems, aligning with national defense strategies to strengthen domestic manufacturing [6][8] - The company is set to finalize multi-state manufacturing operations to support the deployment of autonomous systems for U.S. and allied forces [6][8]

CEO-directed visit to Seoul focuses on collaborative cross-border brokerage, investor tools, and next-gen infrastructureNEW YORK and SEOUL, South Korea, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Siebert Financial Corp. (Nasdaq: SIEB) today confirmed senior-level working sessions with Kakao Pay and Kakao Pay Securities on August 20–21 in Pangyo and Yeouido. The visit was directed by Siebert CEO John J. Gebbia to expand and deepen a partnership that supports clients in South Korea and the United States, thanks chiefl ...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September. Details are as follows: Citi’s 2025 Biopharma Back to School Conference Location: Boston, MADate: Tuesday, September 2, 2025 Cantor Global Healthcare Confe ...

VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that its field crews have mobilized back to the Robinsons River Salt Project in Newfoundland and Labrador to begin the recollection of Ambient Noise Tomography (“ANT”) sensors. This marks a milestone in the ANT survey program, as the sensors have now completed their required data collection period. The retrieval process will allow the Compa ...

Core Perspective - Genmab A/S announced that the U.S. FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S) for treating adult patients with recurrent or progressive endometrial cancer who have experienced disease progression after prior treatments [2][7] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics, with a vision to transform the lives of patients with cancer and other serious diseases by 2030 [10][11] Product Development - Rina-S is an investigational antibody-drug conjugate targeting folate receptor alpha (FRα) and is currently undergoing late-stage development, including ongoing Phase 1/2 and Phase 3 trials for various cancers [4][8] - The Breakthrough Therapy Designation is supported by results from the Phase 1/2 RAINFOL™-01 trial, which showed encouraging responses in heavily pretreated endometrial cancer patients [3][7] Clinical Trial Insights - The RAINFOL™-01 trial is an open-label, multicenter study designed to evaluate the safety and efficacy of Rina-S in solid tumors expressing FRα, with multiple cohorts focusing on different cancer types [5][8] - The trial's B2 cohort included 64 patients with advanced or recurrent endometrial cancer who had progressed after anti-PD-(L)1 and platinum-based chemotherapy [3][6] Market Context - Endometrial cancer is the second most prevalent gynecologic cancer globally, with increasing incidence and limited treatment options for advanced cases, highlighting the need for innovative therapies like Rina-S [6][8]

ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations website. Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET. Live webcasts can be accessed on the investor and media se ...